Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)

BACKGROUND: Despite sensitivity to first-line chemotherapy, most small-cell lung cancer (SCLC) patients relapse. In this setting, topotecan demonstrated modest activity with significant toxicity. Paclitaxel was also active. This study was designed to evaluate activity and safety of nab-paclitaxel in...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Br J Cancer
Egile Nagusiak: Gelsomino, Francesco, Tiseo, Marcello, Barbieri, Fausto, Riccardi, Ferdinando, Cavanna, Luigi, Frassoldati, Antonio, Delmonte, Angelo, Longo, Lucia, Dazzi, Claudio, Cinieri, Saverio, Colantonio, Ida, Sperandi, Francesca, Lamberti, Giuseppe, Brocchi, Stefano, Tofani, Lorenzo, Boni, Luca, Ardizzoni, Andrea
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7341887/
https://ncbi.nlm.nih.gov/pubmed/32346071
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-0845-3
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak